DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for mucopolysaccharidosis type 4A — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMucopolysaccharidosis type 4A maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mucopolysaccharidosis type 4a is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
alpha-L-iduronidase (IDUA) — IDUA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{r},2~{r},3~{r},4~{s},6~{s}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6I6R · 2.02 Å · ligand (1~{R},2~{R},3~{R},4~{S},6~{S})-6-azanyl-2,3,4-tris(oxidanyl)cyclohexane-1-carboxylic acid (H62). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts provided do not contain original research on mucopolysaccharidosis type 4A, and none of them report any clinical trial, treatment outcome, or drug efficacy data for this condition. The first abstract concerns a single eight-year-old patient with mucopolysaccharidosis type II (Hunter’s syndrome), not type 4A, and describes a urinary glycosaminoglycan level of 69.6 mg/mmol against a normal range of 0.0–11.6 mg/mmol, with elevated heparan sulphate on electrophoresis. The authors emphasise that diagnosis was delayed by five years and that severe cardiovascular complications had already developed, attributing this to the scarce availability and high cost of enzyme activity testing in a resource-limited country. No therapeutic intervention or outcome is reported.
The second abstract is a general review of challenges in mucopolysaccharidosis type I, covering classification, neonatal screening, spinal and eye disease care, allergic reactions to enzyme replacement therapy, and transition to adult care. It provides no numerical data, no patient cohorts, and no results for any drug. The remaining two entries are identical supplemental files for a case report on limited diagnostic facilities for mucopolysaccharidosis in Bangladesh; their content is not described in the supplied text, but the title indicates a focus on diagnostic barriers rather than treatment efficacy.
Taken together, these documents offer no evidence relevant to repurposing any drug for mucopolysaccharidosis type 4A. There are no response rates, survival figures, or sample sizes to quote because none were reported. The consistent theme across the abstracts is diagnostic delay and lack of access to enzyme testing in developing countries, not therapeutic success or failure. What is missing is any clinical data on enzyme replacement therapy, substrate reduction, or gene therapy for type 4A specifically, along with any controlled trial design, patient stratification by phenotype, or long-term follow-up. Funding for newborn screening programmes and affordable diagnostic infrastructure would be needed before any treatment could be evaluated in the populations described.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Ethiopian Journal of Health Sciences · 2015 · 5 citations · open access
Challenges in the Management of Mucopolysaccharidosis Type II (Hunter’s Syndrome) in a Developing Country: a Case Report
AbstractBACKGROUND: Mucopolysaccharidosis type II (Hunter's syndrome) is an X-linked chromosomal storage disorder due to deficiency of the lysosomal enzyme iduronate-2-sulfatase with patients rarely living till adulthood. Failure to identify patients early could contribute to an increased morbidity as identified in this case report. CASE DETAILS: An eight year old patient with Hunter's syndrome identified five years after disease onset with severe cardiovascular complications exemplifies the challenges faced in resource-limited countries towards making diagnosis and treatment of rare conditions. Elevated urinary glycosaminoglycans levels or a strong clinical suspicion of Hunter's syndrome, as identified in the index case, is a prerequisite for enzyme activity testing. Urinary mucopolysaccharide(MPS) level was 69.6 mg/mmol(normal range is 0.0 - 11.6 mg/mmol), and the confirming MPS electrophoresis analysis showed elevated heparan sulphate in the urine sample. Enzyme activity testing, with absent or very low iduronate-2-sulfatase activity, is diagnostic. However, the scarce availability and high cost of these tests is another constraint in making a diagnosis. CONCLUSION: Identification and management of mucopolysaccharidosis type II pose a problem in resource-constrained countries due to late presentation, lack of facility for diagnosis and treatment, cost and expertise required for the management.
Archivos Argentinos de Pediatria · 2021 · 0 citations · open access
Algunos desafíos en mucopolisacaridosis tipo I
AbstractHere we describe the current challenges of mucopolysaccharidosis type I: the need for an adequate classification, establishing its relationship to therapeutic indications; an early diagnosis, from neonatal screening, its advantages and barriers, to clinical suspicion of severe and attenuated forms; spinal and eye disease care, from diagnosis to follow-up and treatment; allergic reactions caused by enzyme replacement therapy, their diagnosis and treatment. And lastly, transition to adult care.
INDIGO (University of Illinois at Chicago) · 2022 · 0 citations · open access
sj-pdf-1-imr-10.1177_03000605221106412 - Supplemental material for Limited diagnostic facilities impeding the therapeutic approach of Mucopolysaccharidosis in Bangladesh: a case report
AbstractSupplemental material, sj-pdf-1-imr-10.1177_03000605221106412 for Limited diagnostic facilities impeding the therapeutic approach of Mucopolysaccharidosis in Bangladesh: a case report by Orindom Shing Pulock, Susmita Dey Pinky and Syeda Humaida Hasan in Journal of International Medical Research
Sage Journals Data · 2022 · 0 citations · open access
sj-pdf-1-imr-10.1177_03000605221106412 - Supplemental material for Limited diagnostic facilities impeding the therapeutic approach of Mucopolysaccharidosis in Bangladesh: a case report
AbstractSupplemental material, sj-pdf-1-imr-10.1177_03000605221106412 for Limited diagnostic facilities impeding the therapeutic approach of Mucopolysaccharidosis in Bangladesh: a case report by Orindom Shing Pulock, Susmita Dey Pinky and Syeda Humaida Hasan in Journal of International Medical Research
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
